• Nasopharyngeal carcinoma (NPC) patients with N2-3 diseases are prone to develop distant metastasis even treated with standard concurrent chemoradiotherapy (CCRT). (oncotarget.com)
  • Platinum-based concurrent chemoradiotherapy represents the gold standard in the treatment of locally advanced nasopharyngeal carcinoma (NPC) [ 1 , 2 ] in the era of 2D radiotherapy. (oncotarget.com)
  • Outcomes of induction chemotherapy followed by concurrent chemoradiation for nasopharyngeal carcinoma. (uchicago.edu)
  • Concurrent chemoradiotherapy followed by adjuvant cisplatin-gemcitabine versus cisplatin-5-fluorouracil chemotherapy for N2-3 nasopharyngeal carcinoma: A multicentre, open-label, randomized, controlled, phase 3 trial. (altaioncology.com)
  • The efficacy and safety of nimotuzumab (NTZ) added to concurrent chemoradiotherapy (CCRT) was investigated in patients with stage III-IVa nasopharyngeal carcinoma (NPC). (researchsquare.com)
  • According to the 2021 Chinese Society of Clinical Oncology and American Society of Clinical Oncology guidelines for nasopharyngeal carcinoma, concurrent chemoradiotherapy (CCRT) is still recommended as the standard treatment for stage II-IVa NPC patients (Yu-Pei Chen et al. (researchsquare.com)
  • The current standard of care for locally advanced nasopharyngeal carcinoma of gemcitabine/cisplatin induction followed by concurrent chemoradiotherapy was established by Zhang et al in 2019. (ascopost.com)
  • 5 Both trials reported benefits from the addition of PD-1 inhibitors regardless of PD-L1 expression, suggesting the addition of immunotherapy to chemotherapy may soon become standard of care for patients with nasopharyngeal carcinoma in both curative and recurrent/metastatic disease. (ascopost.com)
  • On the basis of this background, we retrospectively explored the possible treatment option and hypothesized that patients with bulky lymph nodes would benefit from additional chemotherapy other than the concurrent modality. (oncotarget.com)
  • In the absence of similar research, we endeavored to investigate the prognostic usefulness of posttreatment neutrophil-to-lymphocyte ratio (NLR) in patients treated with definitive concurrent chemoradiotherapy (CCRT) for locally advanced pancreatic adenocarcinoma (LAPAC). (hindawi.com)
  • however, chemotherapy (CT), concurrent chemoradiotherapy (CCRT), and induction CT followed by CCRT are the most often utilized alternatives [ 6 ]. (hindawi.com)
  • A phase I dose escalation study of Ad GV.EGR.TNF.11D (TNFerade™ Biologic) with concurrent chemoradiotherapy in patients with recurrent head and neck cancer undergoing reirradiation. (uchicago.edu)
  • Prior chemoradiotherapy adversely impacts outcomes of recurrent and second primary head and neck cancer treated with concurrent chemotherapy and reirradiation. (uchicago.edu)
  • Adjuvant chemotherapy prior to postoperative concurrent chemoradiotherapy for locoregionally advanced head and neck cancer. (uchicago.edu)
  • Characteristics associated with swallowing changes after concurrent chemotherapy and radiotherapy in patients with head and neck cancer. (uchicago.edu)
  • Numerous studies have demonstrated that chemotherapy concurrent to radiation therapy provides better tumor control and more favorable outcomes (M. X. Zhang et al. (researchsquare.com)
  • Treatments were assigned based on clinical TNM stage and patient health: stage I patients received radiotherapy alone, stage II patients received radiotherapy alone or platinum-based concurrent radiochemotherapy, and advanced-stage patients (stage III through stage IV) were given concurrent chemoradiotherapy and neoadjuvant or adjuvant chemotherapy. (cancertherapyadvisor.com)
  • The CONTINUUM trial randomly assigned 425 patients in China with stage III/IV nasophargyneal carcinoma to receive gemcitabine/cisplatin induction followed by concurrent chemoradiotherapy with or without sintilimab, a novel PD-1 antibody with a higher affinity for PD-1 than other immune checkpoint inhibitors. (ascopost.com)
  • Adjuvant durvalumab after concurrent chemoradiotherapy for patients with unresectable stage III NSCLC harbouring uncommon genomic alterations. (cdc.gov)
  • The PREOPANC-2 trial investigates whether neoadjuvant FOLFIRINOX improves OS compared with neoadjuvant gemcitabine-based chemoradiotherapy and adjuvant gemcitabine in resectable and borderline resectable pancreatic cancer patients. (nih.gov)
  • Patients receive 8 cycles of neoadjuvant FOLFIRINOX chemotherapy followed by surgery without adjuvant treatment (arm A), or 3 cycles of neoadjuvant gemcitabine with hypofractionated radiotherapy (36 Gy in 15 fractions) during the second cycle, followed by surgery and 4 cycles of adjuvant gemcitabine (arm B). The primary endpoint is OS by intention-to-treat. (nih.gov)
  • Adjuvant therapy with gemcitabine is accepted as standard therapy for surgically resected pancreatic cancer. (medscape.com)
  • Further therapeutic advances and prospective trials are needed to better define the optimal role of adjuvant and neoadjuvant treatment in patients with resectable pancreatic cancer. (cancernetwork.com)
  • BACKGROUND: The role of adjuvant therapy in patients with oesophagogastric adenocarcinoma treated by neoadjuvant chemotherapy is contentious. (ljmu.ac.uk)
  • Predictive and prognostic markers to adjuvant systemic chemotherapy have been identified, with the goal of tailoring therapy and continuing improvement in survival. (northwestern.edu)
  • CONCLUSIONS: Adding modified FOLFOX6 after chemoradiotherapy and before total mesorectal excision increases compliance with systemic chemotherapy and disease-free survival in patients with locally advanced rectal cancer. (elsevierpure.com)
  • High-grade glioma (HGG) are optimally treated with maximum safe surgery, followed by radiotherapy (RT) and/or systemic chemotherapy (CT). (surgicalneurologyint.com)
  • Therefore, in some views, tumor downstaging, especially pCR, was regarded as a goal in neoadjuvant treatment of locally advanced rectal cancer, which motivated the combination of systemic chemotherapy and advanced RT technique in this approaches. (biomedcentral.com)
  • The RENAISSANCE (AIO-FLOT5) trial: effect of chemotherapy alone vs. chemotherapy followed by surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction - a phase III trial of the German AIO/CAO-V/CAOGI. (helsedirektoratet.no)
  • Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial. (helsedirektoratet.no)
  • Among them, new adjuvant chemoradiotherapy followed by selective radical resection of rectal cancer is one of the generally recognized methods for the treatment of advanced rectal cancer [ 13 - 15 ]. (hindawi.com)
  • Although surgical resection remains the cornerstone of treatment, local and distant failure rates are high after complete resection, and debate continues as to the appropriate adjuvant therapy. (cancernetwork.com)
  • 2,3] Local and/or distant recurrence is common following resection, highlighting the importance of adjuvant therapy. (cancernetwork.com)
  • Rami Manochakian, MD , of Mayo Clinic Florida, offers his perspective on the new phase III findings on osimertinib, a third-generation, central nervous system EGFR tyrosine kinase inhibitor, which demonstrated an unprecedented overall survival benefit for patients with EGFR -mutated, stage IB-IIIA non-small cell lung cancer (NSCLC) after complete tumor resection, with or without adjuvant chemotherapy (Abstract LBA3). (ascopost.com)
  • Generally, clinically staged T1N + M0 and T2-T4aN(any)M0 gastric cancer requires surgical resection with adequate lymphadenectomy, together with perioperative or adjuvant chemotherapy. (frontiersin.org)
  • Treatment options for NSCLC depend upon disease stage and range from surgical resection or radiotherapy (stage 1) through to surgery and adjuvant chemotherapy or chemo-radiotherapy for those with stage 3. (hospitalhealthcare.com)
  • Adjuvant therapy following oesophagectomy for adenocarcinoma in patients with a positive resection margin. (ljmu.ac.uk)
  • In UK practice, surgical resection margin status is often used to classify patients for receiving adjuvant treatment. (ljmu.ac.uk)
  • The aim of this study was to assess the survival benefit of adjuvant therapy in patients with positive (R1) resection margins. (ljmu.ac.uk)
  • CONCLUSION: Adjuvant therapy may improve overall survival and recurrence-free survival after margin-positive resection. (ljmu.ac.uk)
  • Historically, after surgical resection adjuvant therapy would be delivered if high-risk features were discovered upon pathologic examination of the surgical specimen. (biomedcentral.com)
  • Treatment is surgical resection and chemotherapy for nodal involvement. (msdmanuals.com)
  • Treatment is surgical resection and chemotherapy for nodal. (msdmanuals.com)
  • CHICAGO - Many patients with locally advanced rectal cancer who do not have high-risk disease can skip radiotherapy to the pelvic area, and instead be treated with chemotherapy alone and then surgery, say researchers reporting results from the PROSPECT trial. (medscape.com)
  • Until now, a series of novel adjuvant chemoradiotherapy have been recommended for patients with TNM stage rectal cancer [ 16 ]. (hindawi.com)
  • Combined multimodality treatments, including radiation, chemotherapy, and total mesorectal excision have been studied extensively over the past few decades, with efforts toward improving rates of locoregional recurrence and disease-free and overall survival in rectal cancer. (northwestern.edu)
  • Vergo, M, Nimeiri, H & Benson, AB 2009, ' Adjuvant chemotherapy after neoadjuvant chemoradiation and surgery: A quest to improve survival for stage II and III rectal cancer ', Current Colorectal Cancer Reports , vol. 5, no. 3, pp. 151-157. (northwestern.edu)
  • Distant metastasis has been the main failure pattern for locoregionally advanced rectal cancer (LARC) patients, and intensified neoadjuvant chemotherapy has become a popular research topic. (biomedcentral.com)
  • Methods: Between 2007 and 2017, patients with clinically staged II-III rectal cancer who were treated with preoperative chemoradiotherapy using either triweekly XELOX (oxaliplatin 130 mg/m 2 plus capecitabine 825 mg/m 2 ) or capecitabine were included. (biomedcentral.com)
  • BACKGROUND: Adding modified FOLFOX6 (folinic acid, fluorouracil, and oxaliplatin) after chemoradiotherapy and lengthening the chemoradiotherapy-to-surgery interval is associated with an increase in the proportion of rectal cancer patients with a pathological complete response. (elsevierpure.com)
  • 20 - 25 ] A major pooled analysis evaluating the impact of T and N stage and treatment on survival and relapse in patients with rectal cancer who are treated with adjuvant therapy confirmed these findings. (cancer.gov)
  • In 2004, a randomized trial from Germany was published establishing a regimen of preoperative chemoradiotherapy and surgery followed by additional cycles of chemotherapy alone as the standard of care for clinical stages T3 or T4, or for node-positive rectal cancer [ 3 ]. (biomedcentral.com)
  • Other clinical studies from the United States, Europe, and Asia have also influenced the treatment strategies for operable rectal cancer, as various approaches using preoperative or postoperative radiotherapy, with or without chemotherapy, have been examined. (biomedcentral.com)
  • This study was designed to explore whether an intensified chemoradiotherapy (CRT) led to a better clinical outcome in locally advanced rectal cancer. (biomedcentral.com)
  • Iwase H, Indo T, Shimada M, Tsuzuki T, Nakarai K, Kaida S, Doi R, Okeya M and Kato E: Esophageal cancer with colonic metastasis successfully treated by chemoradiotherapy followed by chemotherapy with S-1 and cisplatin. (spandidos-publications.com)
  • Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. (helsedirektoratet.no)
  • This is a case report of a 77-year-old Spanish male patient with localized SCC of the colon, who presented a pathological complete response in the surgical specimen after neoadjuvant chemotherapy with cisplatin and etoposide. (mdpi.com)
  • 2021 ). Cisplatin-based chemotherapy with intensity-modulated radiotherapy (IMRT) is the standard care for NPC patients in recent years. (researchsquare.com)
  • Population-based survival and costs of pancreas adenocarcinoma patients receiving adjuvant chemoradiation and chemotherapy following pancreaticoduodenectomy are poorly understood. (hopkinsacg.org)
  • This retrospective cohort study used linked administrative and pathological datasets to identify all patients diagnosed with pancreas adenocarcinoma and undergoing pancreaticoduodenectomy in Ontario between April 2004 and March 2014, who received postoperative chemoradiation or chemotherapy. (hopkinsacg.org)
  • Median overall health system costs were calculated at 1 and 3 years for chemoradiation and chemotherapy, and differences were tested using the Kruskal-Wallis test. (hopkinsacg.org)
  • Median survival was 19 months for chemoradiation and 22 months for chemotherapy. (hopkinsacg.org)
  • Patients receiving chemoradiation were more likely to have positive margins: 47.7% compared with 19.2% in chemotherapy. (hopkinsacg.org)
  • Overall 1-year health system costs were significantly higher for chemoradiation (USD $70,047) than chemotherapy (USD $54,005) ( p ≤ 0.001). (hopkinsacg.org)
  • Chemotherapy and chemoradiation yielded similar survival, but chemoradiation resulted in higher costs. (hopkinsacg.org)
  • Others, however, view locoregional failure as a significant contributor to morbidity and mortality, thereby justifying the use of adjuvant chemoradiation. (cancernetwork.com)
  • Final Results of a Randomized Phase 2 Trial Investigating the Addition of Cetuximab to Induction Chemotherapy and Accelerated or Hyperfractionated Chemoradiation for Locoregionally Advanced Head and Neck Cancer. (uchicago.edu)
  • Although surgical advances including total mesorectal excision continue to decrease rates of local recurrence, the management of locally advanced disease (T3-T4 or N+) benefits from a multimodality approach including neoadjuvant concomitant chemotherapy and radiation. (biomedcentral.com)
  • Local and distant recurrence rates after non-total mesorectal excision (TME) surgery alone are as high as 40%-60% [ 2 ], thus warranting adjuvant therapy to improve local/regional control. (biomedcentral.com)
  • [ 3 ] . For patients who received preoperative chemotherapy, the addition of postoperative radiotherapy has not demonstrated additional benefit. (medscape.com)
  • The present study aimed to compare the survival outcomes, acute toxicities and surgical complications in LARC patients who received preoperative chemoradiotherapy with triweekly oxaliplatin and capecitabine (triweekly XELOX) or capecitabine. (biomedcentral.com)
  • However, the reports were both based on small sample sizes, and no clear evidence exists for the superiority of triweekly XELOX compared to capecitabine alone with preoperative chemoradiotherapy in patients with LARC. (biomedcentral.com)
  • The mean number of total chemotherapy cycles differed among the 4 groups (p = 0.002), because one third of patients in the group assigned to no preoperative FOLFOX did not receive any adjuvant chemotherapy. (elsevierpure.com)
  • A concomitant boost to oxalipatin-combined preoperative chemoradiotherapy demonstrated a slightly higher pCR rate but delayed incision healing after surgery. (biomedcentral.com)
  • Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. (helsedirektoratet.no)
  • Therefore, we designed this randomized trial to explore whether a combined regimen of oxaliplatin-added chemoradiotherapy and a concomitant boost to the primary tumor would further lead to a better clinical outcome. (biomedcentral.com)
  • The association between chemotherapy regimens and survival endpoints, including distant metastasis-free survival (DMFS), overall survival (OS) and disease-free survival (DFS), were evaluated and adjusted with PS. (biomedcentral.com)
  • Furthermore, several randomised trials have shown that the addition of alkylating chemotherapy, either temozolomide or nitrosourea-based regimens, to radiotherapy results in prolonged survival. (smw.ch)
  • Two recent randomized trials have suggested benefit of neoadjuvant chemoradiotherapy over upfront surgery, both including single-agent chemotherapy regimens. (nih.gov)
  • Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. (helsedirektoratet.no)
  • The phase III IMpassion130 trial comparing chemotherapy plus atezolizumab versus chemotherapy plus placebo brought breast cancer into the immunotherapy era. (biomedcentral.com)
  • P = 0·004) were observed for adjuvant chemoradiotherapy versus no adjuvant treatment. (ljmu.ac.uk)
  • Kaplan-Meier and Cox proportional hazards regression survival analyses were used to determine associations between adjuvant treatment approach and survival, while stratifying by margin status. (hopkinsacg.org)
  • Among the treatments for improving survival in women with high-risk and early-stage endometrial cancer are radiation plus chemotherapy, vaginal cuff brachytherapy plus chemotherapy, and adjuvant chemotherapy. (medpagetoday.com)
  • The first study was the Phase III randomized Gynecologic Oncology Group (GOG)-249 trial, which compared vaginal cuff brachytherapy plus chemotherapy with pelvic radiation therapy for endometrial cancer, with a principal focus on recurrence-free survival. (medpagetoday.com)
  • The results showed an increase in failure-free survival, 75.5% in the chemoradiotherapy arm, compared with 68.6% in the patients treated with radiation only, but the 5-year survival rate did not improve with the addition of adjuvant chemotherapy. (medpagetoday.com)
  • Improving survival in women with high-risk, early-stage (stages I-II) endometrial cancer has been the goal of research exploring various modalities such as radiation plus chemotherapy, vaginal cuff brachytherapy plus chemotherapy, and adjuvant chemotherapy. (medpagetoday.com)
  • The aim of this retrospective study is to investigate therapeutic patterns and survival outcomes for a cohort of older NPC patients receiving radiation therapy (RT) with or without chemotherapy (CT). (jcancer.org)
  • 11 ] demonstrated a substantial overall survival (OS) benefit in patients with PD-L1-positive (PD-L1 + ) metastatic or inoperable locally advanced TNBC through the addition of the anti-PD-L1 agent atezolizumab to first-line chemotherapy with nab-paclitaxel. (biomedcentral.com)
  • Here, we review the literature and report a unique case of a patient with a vague presentation of esophageal neuroendocrine carcinoma as he enters his sixth year of survival following neoadjuvant chemoradiotherapy. (biomedcentral.com)
  • Adjusted Cox regression analyses were used to compare overall and recurrence-free survival according to adjuvant treatment. (ljmu.ac.uk)
  • They were all treated with Intensity-modulated radiation therapy (IMRT) combined with systemic treatments, including radiotherapy alone (RT alone), neoadjuvant chemotherapy followed by radiotherapy (NACT+RT), CCRT, NACT+CCRT, NACT followed by radiotherapy and adjuvant chemotherapy (NACT+RT+AC), CCRT+AC and NACT+CCRT+AC. (oncotarget.com)
  • A randomized phase III study of adjuvant platinum/docetaxel chemotherapy with or without radiation therapy in patients with gastric cancer. (helsedirektoratet.no)
  • The other study, PORTEC (Post-Operative Radiation Therapy in Endometrial Carcinoma), compared the standard of care with adjuvant chemotherapy during and after radiotherapy for patients with high-risk endometrial cancer. (medpagetoday.com)
  • The Phase III randomized Gynecologic Oncology Group (GOG)-249 trial, presented at the most recent American Society for Radiation Oncology (ASTRO) annual meeting , compared vaginal cuff brachytherapy plus chemotherapy with pelvic radiation therapy for the treatment of stage I-II high-risk, early-stage endometrial cancer. (medpagetoday.com)
  • Of the 601 patients accrued, 301 were assigned to the pelvic external-beam radiation therapy (PXRT) arm and 300 were assigned to the vaginal cuff brachytherapy and chemotherapy (VCB/C) arm. (medpagetoday.com)
  • Treatment may consist of some combination of surgery, chemotherapy, and radiation therapy. (wikipedia.org)
  • However, surgery is increasingly incorporated in a multimodality approach that includes neoadjuvant and adjuvant chemotherapy and/or radiation therapy. (medscape.com)
  • However, an important role exists for chemotherapy and/or radiation therapy. (medscape.com)
  • A total of 363 plasma samples from 88 patients with early-stage NSCLC (stages 1, 2 and 3) treated with curative intent surgery (61), surgery and adjuvant chemotherapy/radiotherapy (8) and chemo-radiotherapy (19) were included in the study. (hospitalhealthcare.com)
  • Despite the benefits from adjuvant chemotherapy or chemoradiotherapy, approximately one-third of stage II gastric cancer (GC) patients developed recurrences. (duke.edu)
  • An all-chemotherapy approach may make curative intent treatment accessible for patients in these resource-constrained settings. (medscape.com)
  • The authors concluded that their data supported the clinical utility of ctDNA testing to identify residual disease and recurrence and that this was a potentially sensitive tool to determine which patients were at high risk of relapse and who could benefit from additional adjuvant therapy. (hospitalhealthcare.com)
  • A prospectively defined cut-point for GCPS classified 22.7% of validation cohort treated with chemoradiotherapy (N=216) as high-risk group with 5-year recurrence rate of 58.6% compared to 85.4% in the low risk group (hazard ratio for recurrence=3.16, p=0.00004). (duke.edu)
  • Impact of the 12-gene recurrence score in influencing adjuvant chemotherapy prescription in mismatch repair proficient stage II/III colonic carcinoma-a systematic review and meta-analysis. (cdc.gov)
  • 7] Additionally, the inclusion of both CRT and adjuvant CT after surgery evaluated two treatment variables, making it difficult to discern the true effect of either treatment alone. (cancernetwork.com)
  • The GCPS was validated in another set with stage II GC who underwent surgery without adjuvant treatment (N=300). (duke.edu)
  • Patients were recommended to receive adjuvant chemotherapy after surgery to complete a total of 8 cycles of modified FOLFOX6. (elsevierpure.com)
  • Due to its rarity, no standardized guidelines have been proposed to treat esophageal neuroendocrine carcinoma, although general recommendations suggest surgery with adjuvant chemoradiotherapy as the treatment of choice. (biomedcentral.com)
  • o It is strongly recommended that patients should be enrolled no more than 8 weeks after surgery, and prior to post-operative chemotherapy (as applicable). (who.int)
  • Concomitant with radiation, fluorouracil based chemotherapy remains the standard, and although toxicity is decreased with continuous infusion fluorouracil, oral capecitabine is non-inferior to the continuous infusion regimen. (biomedcentral.com)
  • Approximately 60% of the enrolled patients (451 for each treatment arm) experienced relapse after prior adjuvant/neoadjuvant treatment, while 37% presented with de novo stage IV disease. (biomedcentral.com)
  • Triweekly XELOX was not associated with an increased risk of severe toxicity during chemoradiotherapy, but it increased the risk of postoperative complications compared to capecitabine. (biomedcentral.com)
  • There are numerous results from clinical trials looking at combined radiation treatment (RT) and chemotherapy for NPC. (intechopen.com)
  • 4,5] Despite the use of neoadjuvant and adjuvant therapies, little progress has been made in the last three decades, and the search for more efficacious treatment continues. (cancernetwork.com)
  • According to the systemic treatment modalities delivered, we classified all 547 patients into non-adjuvant chemotherapy (non-AC) group (341 patients) and adjuvant chemotherapy (AC) group (206 patients). (oncotarget.com)
  • It is indicated for maintenance treatment of adults with deleterious or suspected deleterious gBRCAm metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen. (medscape.com)
  • Variables potentially influencing chemotherapy treatment selection were used to generate propensity scores (PS). (biomedcentral.com)
  • aTTom - adjuvant Tamoxifen Treatment Offer more? (birmingham.ac.uk)
  • Recent advances in neoadjuvant or adjuvant chemotherapy/chemoradiotherapy for treatment of ESCC have significantly improved prognosis. (hku.hk)
  • Strategies being investigated include reductions in radiation dose, response-tailored dose reduction after induction chemotherapy, and use of novel biomarkers such as HPV circulating tumor DNA to guide treatment. (ascopost.com)
  • Of these, 112 patients (46·3 per cent) received adjuvant chemoradiotherapy, 46 (19·0 per cent) were treated with adjuvant chemotherapy and 84 (34·7 per cent) had no adjuvant treatment. (ljmu.ac.uk)
  • There are limited data of randomized clinical trials with adjuvant chemotherapy to support evidence-based decision-making [ 6 - 8 ]. (oncotarget.com)
  • Many advances in RT techniques and schedules are attempted to improve outcomes of the disease starting from intracavitary brachytherapy, intensity modulated RT to simultaneous modulated accelerated RT, all showing some promise with most significant benefit seen with addition of chemotherapy, especially in intermediate (Stage II) and advanced (Stage III, IVA, IVB) cases. (intechopen.com)
  • Olaparib has US Food and Drug Administration (FDA) approval for adults with germline BRCA -mutated metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen. (medscape.com)
  • Whereas there were worse neuropathy outcomes at 12 months with mFOLFOX6, the toxicities with chemoradiotherapy "tip the scale" in favor of chemotherapy. (medscape.com)
  • It may depend on whether the long-term neuropathy associated with chemoradiotherapy may be more relevant for some, such as musicians, while the early toxicities with mFOLFOX6 may be unsupportable for people looking after young families. (medscape.com)
  • With a median follow-up time of 53.8 months, adjuvant chemotherapy significantly decreased the risk of distant metastasis (HR 0.413, 95% CI 0.194-0.881, p = 0.022) as well as significantly increased the OS (HR 0.398, 95% CI 0.187-0.848, p = 0.017) in patients with N3 disease. (oncotarget.com)
  • There was also much more toxicity in patients given chemoradiotherapy, which occurred in 198 patients (60%), compared with only 41 patients (12%) who had radiation only. (medpagetoday.com)
  • Chemotherapy based around a doublet or triplet platinum/fluoropyrimidine combination is given for metastatic disease. (medscape.com)
  • The addition of adjuvant chemotherapy seemed to provide benefits to patients with N3 stage NPC and the current study may indicate the need for further randomized investigation. (oncotarget.com)
  • Updated results from the Quarterback trial, presented at ASCO 2023, showed that response to induction chemotherapy may be a reasonable way to select patients for dose-reduced chemoradiotherapy, but further randomized studies are needed to evaluate this approach. (ascopost.com)
  • These results were similarly consistent with the GOG-249 study because it also did not show any additional advantage to giving chemotherapy to endometrial cancer patients. (medpagetoday.com)
  • Our trial clearly demonstrates that adjuvant pelvic radiation should remain the standard of care for high-risk, early-stage endometrial cancer patients," the lead author of the study, Marcus Randall, MD, of the University of Kentucky College of Medicine in Lexington, said in an ASTRO news release. (medpagetoday.com)
  • It also suggests that the trend in our field of abandoning pelvic radiation in favor of chemotherapy-brachytherapy combinations for high-risk patients is premature and not supported by clinical evidence. (medpagetoday.com)
  • In this article, we review the data surrounding the use of chemotherapy (CT) and chemoradiotherapy (CRT) in patients with resectable pancreatic cancer. (cancernetwork.com)
  • Neoadjuvant consolidation chemotherapy may have benefits beyond increasing pathological complete response rates. (elsevierpure.com)
  • Mismatch repair-deficient tumors do not respond well to chemotherapy applied in the neoadjuvant, adjuvant, or metastatic settings. (cancer.gov)